69/21/2818 18:18 Fron: | Voodson C. Merrell M Webfax Page: 5/713 - Loh Gos Bias ee en mre em my Patient: EPSTEIN, JEFFREY Specimen iD: 257-480-2371-.0 DOB: 01/20/1953 Patient ID: Control iD: 5831143092 Date collected: 09/14/2018 1255 Local Vitamin B12 463 pg/mL 232 - 1245 01 Folate (Folic Acid), Serum 4.4 ng/mL >3.0 01 Note: 01 A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency. PSH and LE LH 3.7 mIU/mL 1.7 - 8.6 01 PSH 4.4 alU/mL 1.5 - 12.4 01 C-Reactive Protein, Cardiac 1.56 mg/L 0.00 - 3.00 01 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc Hemoglobin Alc 5.5 % 4.8 - 5.6 01 Please Note: 01 Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.7 ng/mL 0.0 - 4.0 01 Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical Prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. 1.290 ulU/mL 0.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 01 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/ml (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/ml (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Bvaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Date issued: 09/20/18 O832 ET FINAL REPORT Page 4 of 6 This document contains private and canfidential heath information protected by state and federe! law. © 1995-2018 Laboratory Corporation of America® Holdings tyou have received this Gocument in error, please calla Al Rights Reserved - Enterprise Report Version: 1.00 EFTA00314056